Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Recent findings in cancer gene therapy described by researchers from Abbott Laboratories
November 18th, 2008
New research, 'Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors,' is the subject of a report. "Chk1 is the major mediator of cell-cycle checkpoints in response to various forms of genotoxic stress. Although it was previously speculated that checkpoint abrogation due to Chk1 inhibition may potentiate the efficacy of DNA-damaging agents through induction of mitotic catastrophe, there has not been direct evidence proving this process," investigators in the United States report. "Here, through both molecular marker and morphological analysis, we directly demonstrate that specific downregulation of Chk1 expression by Chk1 siRNA potentiates the cytotoxicities...
Source: Cancer Weekly (2008-11-18)
|
